ангиотензинII受体阻断剂导致前列腺特异性抗原水平的变化:一项回顾性队列研究
Ayako Maeda-Minami1, Tomoki Nishikawa1, Hideki Ishikawa2
1Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan.
Anticancer research
|November 29, 2023
概括
抗胰岛素II受体抑制剂 (ARBs) 可能降低前列腺特异性抗原 (PSA) 水平在没有前列腺癌史的日本老年男性. 这一发现表明ARB可以帮助预防前列腺癌.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 药理学 药理学是指药理学的学科.
- 预防医学 预防医学
背景情况:
- 之前的研究表明,血管增生素II受体抑制剂 (ARBs) 在前列腺癌患者中降低前列腺特异抗原 (PSA).
- 关于ARB对未经前列腺癌诊断的人群PSA水平的影响的数据有限.
研究的目的:
- 调查ARBs在没有前列腺癌史的日本男性中对PSA水平升高的潜在抑制作用.
- 在基于人口的队列中评估与ARB使用相关的PSA变异性.
主要方法:
- 对一个大型日本索赔数据库 (2008年4月 - 2019年6月) 的回顾性分析.
- 纳入标准:年龄≥60岁的男性患者,至少有两次PSA测量 (3个月-2年间隔).
- 在服用ARB (ARB组) 和服用其他抗高血压剂 (非ARB组) 的患者之间比较PSA水平的增加.
主要成果:
- 与非ARB组 (n=527) 相比,ARB组中PSA水平升高的患者比例明显较低 (n=777).
- 在ARB组中,PSA升高的调整后几率比为0.80 (95% CI:0.64-0.99,p=0.047).
结论:
- 抗胰岛素II受体抑制剂 (ARBs) 可能在没有前列腺癌史的男性中抑制高PSA水平方面发挥作用.
- ARBs的这种效应可能有助于前列腺癌预防策略.
相关概念视频
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
748
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
748
01:25Antihypertensive Drugs: Direct Renin Inhibitors
637
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
637
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
654
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
654
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
436
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
845
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
845
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
170
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
170